These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12439596)

  • 1. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
    Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
    Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
    Conti JA; Kemeny NE; Saltz LB; Huang Y; Tong WP; Chou TC; Sun M; Pulliam S; Gonzalez C
    J Clin Oncol; 1996 Mar; 14(3):709-15. PubMed ID: 8622015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
    Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
    van Hazel GA; Pavlakis N; Goldstein D; Olver IN; Tapner MJ; Price D; Bower GD; Briggs GM; Rossleigh MA; Taylor DJ; George J
    J Clin Oncol; 2009 Sep; 27(25):4089-95. PubMed ID: 19652069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
    Louvet C; André T; Gamelin E; Garcia ML; Saavedra A; Lenaers G; de Gramont A; Méry-Mignard D; Kalla S
    Bull Cancer; 2004 Dec; 91(12):279-84. PubMed ID: 15634630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
    Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
    Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L; Janik JE
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
    Duffour J; Gourgou S; Desseigne F; Debrigode C; Mineur L; Pinguet F; Poujol S; Chalbos P; Bressole F; Ychou M
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):383-9. PubMed ID: 17124595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Luo HY; Li YH; Zhang L; Jiang WQ; Shi YX; Wang F; He YJ; Xu RH
    Ai Zheng; 2007 Aug; 26(8):905-8. PubMed ID: 17697557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
    Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.